Compare BUR & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BUR | NEO |
|---|---|---|
| Founded | 2009 | 2001 |
| Country | Guernsey | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2017 | 2008 |
| Metric | BUR | NEO |
|---|---|---|
| Price | $4.99 | $8.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $13.58 | $11.14 |
| AVG Volume (30 Days) | ★ 6.1M | 1.4M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $413,360,000.00 | N/A |
| Revenue This Year | $104.62 | $10.63 |
| Revenue Next Year | N/A | $9.73 |
| P/E Ratio | $16.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.59 | $4.72 |
| 52 Week High | $14.61 | $13.74 |
| Indicator | BUR | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 37.83 | 51.59 |
| Support Level | $3.59 | $7.33 |
| Resistance Level | $9.59 | $8.89 |
| Average True Range (ATR) | 0.30 | 0.45 |
| MACD | 0.13 | 0.17 |
| Stochastic Oscillator | 97.31 | 81.79 |
Burford Capital Ltd provides capital against the underlying value of litigation and legal assets, known as legal finance, serving the legal industry with financial products and services. Its business is funding clients engaged in ongoing legal disputes to pay legal fees and monetize the expected future value of disputes, focusing on large, complex matters. The company has two reportable segments: Principal Finance, which earns maximum revenue and allocates capital to legal finance assets from its balance sheet and through interests in private funds managed by the company, and Asset Management and Other Services, which manages legal finance assets for third-party investors and provides other services to the legal industry.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.